ARTICLE | Clinical News
Tenofovir exalidex: Interim Ph IIa data
April 28, 2017 5:57 PM UTC
Interim data from 12 treatment-naïve patients with HBV infection in an open-label, Thai Phase IIa trial showed that once-daily 100 mg oral tenofovir exalidex led to a lower mean HBV viral load after 2...
BCIQ Target Profiles